Literature DB >> 9141556

Metabolism of dexamethasone in the human kidney: nicotinamide adenine dinucleotide-dependent 11beta-reduction.

S Diederich1, B Hanke, W Oelkers, V Bähr.   

Abstract

Recently, two distinct isoenzymes of 11beta-hydroxysteroid-dehydrogenase (11beta-HSD) have been cloned and characterized in several species: The isoenzyme 11beta-HSD-I is widely distributed, bidirectional, prefers NADP(H) and has a low substrate affinity. The isoenzyme 11beta-HSD-II seems to exclusively oxidize physiological glucocorticoids, uses NAD as cosubstrate, has high substrate affinity, and is only found in mineralocorticoid target tissues and the placenta. Synthetic steroids fluorinated in position 9, however, are rapidly reduced by human kidney cortex slices. We attempted to find out which isoenzyme is responsible for this unexpected reductase activity. We studied the 11beta-HSD activity towards cortisol (F)/cortisone (E) and dexamethasone (D)/11-dehydro-dexamethasone (DH-D) in microsomes prepared from human kidney cortex. For the reaction E to F (not for DH-D to D!), glucose-6-phosphate and glucose-6-phosphate-dehydrogenase had to be added as a NADH/NADPH-regenerating system. Oxidation of F to E: NAD was the exclusively used cosubstrate; the affinity [Michael's constant (Km) for F = 25.5 nmol/L] and the maximum velocity (Vmax = 22.9 nmol/mg/min) were high. Reduction of E to F: Without the NADH/NADPH-regenerating system, this reaction was very slow. With this system, the Km value for E was in the nanomolar range (80.6 nmol/L) and the Vmax value was very low (0.88 nmol/mg/min). The reaction was clearly NADH-preferring. For the steroid pair F/E, the quotient Vmax(oxidation)/Vmax(reduction) (=26) demonstrates an equilibrium far on the 11-keto side. Oxidation of D to DH-D: With NAD as the only used cosubstrate, the kinetic analysis is compatible with the existence of two different NAD-dependent isoenzymes: Km for D = 327 nmol/L, Vmax = 53.5 nmol/mg/min and Km for D = 81.2 nmol/L; Vmax = 20.4 nmol/mg/min. Reduction of DH-D to D: The maximum velocity was higher than that of all other reactions tested: Vmax = 226.0 nmol/mg/min. The reaction was exclusively NADH-dependent; the Km value for DH-D was 68.4 nmol/L. For D/DH-D, the ratio Vmax(oxidation)/Vmax(reduction) was 0.24, demonstrating a shift to reductase activity with the reaction equilibrium far on the 11-hydroxy side. The reaction F to E was inhibited by E, DH-D, and D in a concentration-dependent manner. In conclusion, the cosubstrate dependence, the Km value of the oxidation of F and the product inhibition are in good correspondence with data for the cloned human 11beta-HSD-II. The NADH-dependent 11beta-reduction of E and especially of DH-D are inconsistent with the dogma of an unidirectional 11beta-HSD-II. The preference of D for the reductase reaction in human kidney slices is probably caused by the fluor atom in position 9, is catalyzed by 11beta-HSD-II, and leads to an activation of 11-DH-D to D in the human kidney.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9141556     DOI: 10.1210/jcem.82.5.3936

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Differential metabolism of clinically-relevant progestogens in cell lines and tissue: Implications for biological mechanisms.

Authors:  Salndave B Skosana; John G Woodland; Meghan Cartwright; Kim Enfield; Maleshigo Komane; Renate Louw-du Toit; Zephne van der Spuy; Chanel Avenant; Donita Africander; Karl-Heinz Storbeck; Janet P Hapgood
Journal:  J Steroid Biochem Mol Biol       Date:  2019-02-26       Impact factor: 4.292

Review 2.  11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action.

Authors:  Karen Chapman; Megan Holmes; Jonathan Seckl
Journal:  Physiol Rev       Date:  2013-07       Impact factor: 37.312

3.  Across-species meta-analysis of dexamethasone pharmacokinetics utilizing allometric and scaling modeling approaches.

Authors:  Dawei Song; William J Jusko
Journal:  Biopharm Drug Dispos       Date:  2021-03-17       Impact factor: 1.627

Review 4.  Safety perspectives on presently considered drugs for the treatment of COVID-19.

Authors:  Sophie L Penman; Robyn T Kiy; Rebecca L Jensen; Christopher Beoku-Betts; Ana Alfirevic; David Back; Saye H Khoo; Andrew Owen; Munir Pirmohamed; B Kevin Park; Xiaoli Meng; Christopher E Goldring; Amy E Chadwick
Journal:  Br J Pharmacol       Date:  2020-08-13       Impact factor: 8.739

5.  Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women.

Authors:  Wojciech Krzyzanski; Mark A Milad; Alan H Jobe; Thomas Peppard; Robert R Bies; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-01-03       Impact factor: 2.745

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.